276 related articles for article (PubMed ID: 33102797)
1. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Caussy C; Johansson L
Endocrinol Diabetes Metab; 2020 Oct; 3(4):e00134. PubMed ID: 33102797
[TBL] [Abstract][Full Text] [Related]
2. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
[TBL] [Abstract][Full Text] [Related]
5. Radiologic evaluation of nonalcoholic fatty liver disease.
Lee SS; Park SH
World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
7. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.
Jayakumar S; Harrison SA; Loomba R
Curr Hepatol Rep; 2016 Jun; 15(2):86-95. PubMed ID: 27795938
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.
Natarajan Y; Loomba R
J Clin Exp Hepatol; 2022; 12(1):174-179. PubMed ID: 35068797
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.
Schaapman JJ; Tushuizen ME; Coenraad MJ; Lamb HJ
J Magn Reson Imaging; 2021 Jun; 53(6):1623-1631. PubMed ID: 32822095
[TBL] [Abstract][Full Text] [Related]
15. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
Papatheodoridi M; Cholongitas E
Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?
Arulanandan A; Loomba R
Curr Hepatol Rep; 2015 Jun; 14(2):109-118. PubMed ID: 26500833
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography.
Tada T; Nishimura T; Yoshida M; Iijima H
J Med Ultrason (2001); 2020 Oct; 47(4):511-520. PubMed ID: 33089412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
